drugset / Trial / NCT07314567
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
NaSingle-groupOpen-labelTreatment
Summary
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Relapsed/Refractory Systemic lupus erythematosus (SLE)
Timeline
- Start
- 2026-01-01
- Primary completion
- 2027-10-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACE1831 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |